Camrelizumab
Monoclonal antibody targets PDCD1 via inhibition
Trials 527 · started per year
Also used as a comparator or background therapy in 56 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06896422 Background | Jun 2025 → Dec 2026 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 1 | NCT06121557 Background | Nov 2023 → Dec 2026 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT05429398 Background | Jun 2022 → Aug 2023 | neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04929652 Background | Jun 2021 → Jun 2022 | colorectal cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 221 trials | ||||||
| Phase 2 | NCT07691645 Background | Sep 2026 → Aug 2029 expected | hepatocellular carcinoma | Xiang-Qian | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07397442 Background | Mar 2026 → Dec 2027 expected | rectum adenocarcinoma | Beijing Friendship Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07143292 Background | Nov 2025 → Dec 2026 expected | cervical cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07162506 Background | Nov 2025 → Aug 2027 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07312578 Background | Nov 2025 → Nov 2027 expected | esophageal squamous cell carcinoma | Peking University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07059949 Background | Jun 2025 → Jan 2027 expected | rectal cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06802757 Background | May 2025 → Jun 2026 overdue | breast cancer | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06632405 Background | Apr 2025 → Mar 2027 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06817525 Comparator | Nov 2024 → May 2026 overdue | triple-negative breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06329947 Background | May 2024 → Jan 2025 overdue | malignant pancreatic neoplasm | Rui-hua Xu, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06413992 Background | May 2024 → Jun 2026 overdue | endometrial carcinoma, metastatic carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06231680 Background | Jan → Jun 2024 | carcinoma of esophagus, non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06084897 Background | Oct 2023 → Apr 2026 overdue | esophageal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05738434 Background | Mar 2023 → Sep 2025 overdue | digestive system carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 2 | NCT05076682 Background | Jun 2022 → Dec 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05355168 Background | Nov 2021 → Dec 2023 | poisoning | Anhui Provincial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04937673 Background | Jul 2021 → Sep 2022 | esophageal squamous cell carcinoma | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT04830267 Background | Mar 2021 → Aug 2024 overdue | nasopharyngeal carcinoma | Chongqing University Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04514081 Comparator | Aug 2020 → Aug 2022 | classic Hodgkin lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04102982 Comparator | Nov 2019 → Oct 2021 | non-small cell lung carcinoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04135690 Background | Oct 2019 → Dec 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07251062 Comparator | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07309419 Comparator | Dec 2025 → Jun 2030 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06796803 Background | Feb 2025 → Feb 2028 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06354530 Background | Mar 2024 → Dec 2025 overdue | esophageal squamous cell carcinoma | Army Medical Center of PLA | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06335355 Comparator | Mar 2024 → Oct 2028 expected | non-small cell lung carcinoma | Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05576272 Comparator | May 2022 → Dec 2024 | nasopharyngeal carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05809336 Background | May 2019 → Oct 2022 | neoplasm | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT07432087 Background | Feb 2026 → Dec 2030 expected | head and neck squamous cell carcinoma | Yue He, MD | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07267806 Background | Oct 2025 → Oct 2029 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Linhui Peng | Recruiting | No outcome recorded |
| Phase 3 | NCT06669611 Comparator | Nov 2024 → Nov 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06485466 Background | Aug 2024 → Jun 2026 overdue | hepatocellular carcinoma | Guohui Xu | Recruiting | No outcome recorded |
| Phase 3 | NCT06533384 Comparator | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06675214 Background | Jul 2024 → Jul 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06438627 Background | May 2024 → May 2026 overdue | nasopharyngeal carcinoma | XIANG YANQUN | Recruiting | No outcome recorded |
| Phase 3 | NCT06239727 Background | Mar 2024 → Feb 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06086457 Background | Feb 2024 → Jun 2026 overdue | neoplasm of esophagus | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT06092957 Background | Oct 2023 → Oct 2029 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05999149 Background | Aug 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05854849 Background | May 2023 → Dec 2025 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05789043 Comparator | Mar 2023 → Aug 2026 overdue | cutaneous melanoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT05760378 Background | Mar 2023 → Jan 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05613478 Comparator | Jan 2023 → Nov 2025 overdue | hepatocellular carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT04404491 Comparator | Jun 2020 → Dec 2022 | esophageal cancer | The First Affiliated Hospital of Henan University of Science and Technology | Unknown | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06636591 Background | Dec 2024 → Jan 2026 | Her2-receptor negative breast cancer, female breast carcinoma | Fudan University | Completed | No outcome recorded |
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05532527 Background | Sep 2022 → Sep 2023 | non-small cell lung carcinoma | Henan Provincial People's Hospital | Unknown | No outcome recorded |
| — | NCT05233358 Background | Feb 2022 → Feb 2023 | hepatocellular carcinoma | The Central Hospital of Lishui City | Unknown | No outcome recorded |
| — | NCT07053215 Background | Dec 2020 → Dec 2024 | non-small cell lung carcinoma | The First Hospital of Hebei Medical University | Completed | No outcome recorded |
| — | NCT07537985 Background | Jan 2020 → Aug 2025 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT06991907 Comparator | Jan 2020 → Mar 2025 | hepatocellular carcinoma | Jiangxi Provincial Cancer Hospital | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-09-02 | Incyte Corporation | Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody incyte.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 584 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | camrelizumab | “This study evaluated the efficacy and safety of a novel, fully China-developed combination therapy-comprising inetetamab (an anti-HER2 monoclonal antibody), camrelizumab (an...” PMID 41593669 ↗ Jan 2026488“a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until...” NCT06675214 ↗ “Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer...” NCT03813784 ↗ “Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab...” NCT06259721 ↗ “Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the...” NCT05048017 ↗ “Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or...” NCT06086457 ↗ “Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2,...” NCT05182944 ↗ “The aim of this study is to evaluate the clinical efficacy and safety of D-BACE combined with neoadjuvant chemotherapy and camrelizumab in patients with resectable stage...” NCT07016126 ↗ “We asked whether the anti-PD-1 agent, camrelizumab, combined with the DNA demethylating agent, decitabine, improves progression-free survival (PFS) in patients with...” PMID 33820822 ↗ Apr 2021 “Camrelizumab, a PD-1 inhibitor produced by Hengrui, has been approved for the treatment of various malignant tumors including advanced lung cancer, advanced liver cancer and...” NCT05475678 ↗ “Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗ “NACI group patients received treatment of minimally 2 cycles of ICIs agent (mainly camrelizumab or toripalimab, 200 mg every 3 weeks (200 mg every 3 weeks)) combined with...” NCT07236320 ↗ “All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical...” NCT05554276 ↗ “Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year” NCT05937438 ↗ “ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma” NCT07641010 ↗ “Examples include PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab, camrelizumab, sintilimab) Administered per standard dosing schedule (e.g., every 2-3 weeks)” NCT07277777 ↗ “followed by anti-PD-1 immunotherapy (camrelizumab 200 mg once, every 3 weeks) initiated within 7 days after completion of radiotherapy as first-line therapy.” PMID 38637772 ↗ Apr 2024 “Toripalimab 240 mg on day 1, every 3 weeks, or Tislelizumab 200 mg on day 1, every 3 weeks, or Camrelizumab 200 mg on day 1, every 3 weeks, for 4-6 cycles.” NCT07528183 ↗ “Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W” NCT06170710 ↗ “The purpose of this study was to compare and analyze the effect of Camrelizumab in concurrent chemoradiotherapy of locally recurrent esophageal cancer.” NCT04404491 ↗ “Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.” PMID 33087333 ↗ Oct 2020 “Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)” NCT06740370 ↗ “Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma” NCT04922450 ↗ “Camrelizumab: 200 mg intravenous drip, administered sequentially 3 times after Qibei'an, each in combination with XELOX chemotherapy.” NCT07397442 ↗ “Drug：Anti-PD-1 antibody Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks. Other names：SHR-1210, Camrelizumab” NCT04665362 ↗ “Group A： Albumin-bound paclitaxe (260 mg/m²,d 1)+Carboplatin (AUC=5, d 1)+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;” NCT06817525 ↗ “PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks.” NCT06991907 ↗ “This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy” NCT04723030 ↗ “with camrelizumab at 200 mg via intravenous infusion every 2 weeks until the disease progressed or toxicity became unacceptable” PMID 38239359 ↗ Jan 2024 “PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial.” PMID 34765307 ↗ Oct 2021 “A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC” NCT04950400 ↗ “Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.” PMID 36001228 ↗ Aug 2022 “PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab, Nivolumab), 200mg/dose, iv drip, q3w.” NCT07537985 ↗ “Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on” NCT06032052 ↗ “Immunotherapy, with agents including but not limited to ramucirumab, pembrolizumab, camrelizumab, and tislelizumab.” NCT07691645 ↗ “Immunotherapy regimen: programmed death-1 (PD-1) inhibitor (e.g., Camrelizumab): Day 0, intravenous infusion, Q3W;” NCT07015489 ↗ “Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab.” NCT05233358 ↗ “Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.” NCT04943029 ↗ “Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma” NCT04366128 ↗ “Meanwhile, camrelizumab is administered to enhance the immune cells' ability to target and destroy tumor cells.” NCT07602049 ↗ “To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib” PMID 37261804 ↗ Aug 2023 “PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab), 200mg/dose, iv drip, q3w.” NCT07501351 ↗ “Camrelizumab 200mg,IV,Q2W once every 21 days during the maintenance treatment period, for a maximum of 2 years” NCT06329947 ↗ “PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.” NCT06702566 ↗ “Then, camrelizumab (200mg IV, q3w) and anti-angiogenic drugs were given regularly until disease progression.” PMID 37056765 ↗ Mar 2023 “Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.” NCT04006821 ↗ “PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.” NCT05777707 ↗ “Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy” NCT06313463 ↗ “Oncolytic virus d1 ;Camrelizumab 200mg, d2+AG(Gemcitabine d2/9+Capecitabine d2-d15),q3w；up to 4 cycles;” NCT06346808 ↗ “Camrelizumab was administered to patients with advanced solid tumors who had failed standard therapies.” PMID 32256049 ↗ Mar 2020 “PD-1 inhibitor (Camrelizumab for injection, Aikening): 200 mg per dose, infused over 30 to 60 minutes.” NCT06866951 ↗ “Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab” NCT06084897 ↗ “Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W.” NCT06121700 ↗ “Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period” NCT06354530 ↗ “Camrelizumab was administered intravenously at a dose of 200 mg on the first day of each cycle.” NCT06811844 ↗ “VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration” NCT07589244 ↗ “they will be given Camrelizumab (200 mg, once every two weeks, for a total of 4 cycles)” NCT07154082 ↗ “Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody.” PMID 30213452 ↗ Sep 2018 “Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody.” PMID 30213452 ↗ Sep 2018 “Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.” NCT05761470 ↗ “atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on” NCT04135690 ↗ “Camrelizumab dose: 200mg, intravenous infusion 30-60min, d1 once every 3 weeks;” NCT06055153 ↗ “e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab” NCT06896422 ↗ “a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg” NCT06092957 ↗ “Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced” PMID 32376724 ↗ May 2020 “SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin” NCT05174156 ↗ “Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14.” NCT04715633 ↗ “Camrelizumab for Injection 200 mg intravenously every 3 weeks.” NCT05429398 ↗ “PD-1 Inhibitor (e.g.pembrolizumab, Sintilimab,Camrelizumab )” NCT05322187 ↗ “Camrelizumab maintenance therapy (200mg q21d) up to 1 year.” NCT07162506 ↗ “preoperative PD-1 inhibitor camrelizumab combined with NACT” PMID 37253491 ↗ May 2023 “PD-1 inhibitor (sintilimab or camrelizumab 200mg, d1, q3w)” NCT07016737 ↗ “Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w” NCT04558684 ↗ “SHR1210 (Camrelizumab) and antivascular drug(Famitinib)” NCT05862064 ↗ “camrelizumab (200 mg intravenously once every 3 weeks)” PMID 39756446 ↗ Jan 2025 “Toripalimab, Pembrolizumab and Camrelizumab, etc.” NCT06802757 ↗ “Camrelizumab (200mg intravenously every 3 weeks)” NCT06622031 ↗ “Subjects receive Camrelizumab intravenously.” NCT06739317 ↗ “A: Camrelizumab 200mg IV on days 1 and 22” NCT06339060 ↗ “1. Camrelizumab + Cisplatin + Paclitaxel” NCT07251062 ↗ “Camrelizumab for injection, 200 mg” NCT05042375 ↗ “Camrelizumab 200mg every 3 weeks” NCT06388031 ↗ “Camrelizumab 200 mg, iv, d1, q3W” NCT05556200 ↗ “camrelizumab 200 mg, IV, d1, q3w” NCT04471480 ↗ “Anti-PD-1 Antibody Camrelizumab” NCT04635956 ↗ “Camrelizumab (200mg IV, Q3W)” NCT07491822 ↗ “Camrelizumab for injection” NCT05809336 ↗ “Camrelizumab for Injection” NCT04812002 ↗ “Camrelizumab:200mg,iv,Q2W” NCT04446091 ↗ “Camrelizumab 200mg Q3W” NCT05507411 ↗ “Camrelizumab Injection” NCT05699811 ↗ “Camrelizumab” NCT05008861 ↗ “Camrelizumab” NCT06031597 ↗ |
| Known as | Aikening | “PD-1 inhibitor (Camrelizumab for injection, Aikening): 200 mg per dose, infused over 30 to 60 minutes.” NCT06866951 ↗ |
| Known as | AiRuiKa | “Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the...” NCT05048017 ↗1“Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the...” NCT05438706 ↗ |
| Known as | Apatinib Mesylas | “Apatinib Mesylas is a small-molecule VEGFR tyrosine kinase inhibitor.” NCT04479527 ↗ |
| Known as | CAM | “neoadjuvant short-course radiotherapy (SCRT) followed by camrelizumab (CAM) and CAPOX” PMID 42292847 ↗ May 2026 |
| Known as | Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China) | “Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China)” NCT04642664 ↗1“Camrelizumab (Carelizumab for Injection, Jiangsu Hengrui Medicine, China)” NCT05742750 ↗ |
| Known as | Camrelizumab for Injection | “Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen immunotherapy every three weeks” NCT04510064 ↗3“Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets” NCT05313282 ↗ “Camrelizumab for Injection” NCT04812002 ↗ “Camrelizumab for injection” NCT05809336 ↗ |
| Known as | Carilizumab | “Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma” NCT04588987 ↗ |
| Known as | Carrelizumab | “Carrelizumab is a human high-affinity IgG4 anti-PD-1 monoclonal antibody drug independently developed by Suzhou Henrui Pharmaceutical Co., Ltd., which can selectively block the...” NCT04909866 ↗12“This study is to analyze the safety and efficacy of drug-eluting beads transarterial chemoembolization combined with apatinib and carrelizumab injection in the treatment of ICC...” NCT04834674 ↗ “Carrelizumab: 200mg, ivgtt, d1, q3w Docetaxel 50mg/m2, ivgtt, d1, q14d; Oxaliplatin 85mg/m2, ivgtt, d1, q14d; Calcium folinate 200mg/m2, ivgtt, d1, q14d; 5-fluorouracil...” NCT05610332 ↗ “This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis” NCT04523662 ↗ “Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.” NCT04997837 ↗ “Teripulimab 240mg, injection or Carrelizumab 200mg, injection, every 3 weeks.” NCT05737563 ↗ “Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle.” NCT06199882 ↗ |
| Known as | SHR-1210 | “Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer...” NCT03813784 ↗105“The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally...” NCT04221516 ↗ “Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II...” NCT04126993 ↗ “Clinical Study of PD-1 Monoclonal Antibody SHR-1210 Combined With Epirubicin in the Treatment of Extensive Small Cell Lung Cancer After First-line Treatment Failure” NCT03755115 ↗ “Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma” NCT04609176 ↗ “Drug: Camrelizumab Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity Other Name: SHR-1210” NCT06276933 ↗ “Drug：Anti-PD-1 antibody Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks. Other names：SHR-1210, Camrelizumab” NCT04665362 ↗ “PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)” NCT05076682 ↗ “PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)” NCT06731140 ↗ “Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg.” NCT04706598 ↗ “PD1 inhibitor Camrelizumab(SHR-1210) combined with DNA methyltransferase inhibitor decitabine” NCT04353479 ↗ “camrelizumab (SHR-1210), a drug that has already been approved in China for treatment” NCT05841472 ↗ “Camrelizumab (SHR-1210) is a humanised anti-programmed death-1 (anti PD-1) antibody.” PMID 30213452 ↗ Sep 2018 “Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.” NCT03912857 ↗ “SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.” NCT03701022 ↗ “This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab)” NCT05862064 ↗ “Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.” NCT04068974 ↗ “SHR-1210 is a humanized anti-programmed cell death receptor 1 antibody.” NCT04204577 ↗ “SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin” NCT05174156 ↗ “Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin” NCT04239170 ↗ “SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody” NCT03955354 ↗ “PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.” NCT03311789 ↗ “Camrelizumab(SHR-1210) 200mg, once every 2 weeks” NCT04047017 ↗ “she will receive PD-1 antibody SHR1210 200mg q2w” NCT03805399 ↗ “SHR-1210 was administered 200mg iv every 2 weeks” NCT03793725 ↗ “SHR-6390 combined with Camrelizumab (SHR-1210)” NCT04866381 ↗ “PD-1 monoclonal antibody SHR-1210 and apatinib” NCT04239443 ↗ “anti-PD-1 antibody Camrelizumab (SHR-1210)” NCT04889768 ↗ “Camrelizumab (SHR-1210), 200mg, I.V., Q3W” NCT04564313 ↗ “camrelizumab (SHR-1210) plus apatinib” NCT04035876 ↗ “Apatinib+ SHR-1210（Camrelizumab）” NCT03736863 ↗ “Camrelizumab (SHR-1210)” NCT06731153 ↗ “Drug: SHR1210” NCT03793725 ↗ “SHR-1210” NCT03914352 ↗ |
| Action | Inhibit | “Camrelizumab inhibits PD-1 in non-clinical models” PMID 32256049 ↗ Mar 2020 |
| Modality | Monoclonal antibody | “A fully human monoclonal immunoglobulin (IgG4 subtype)” NCT02721589 ↗ |
| Route | Intravenous | “camrelizumab was administered intravenously at 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks” PMID 32256049 ↗ Mar 2020 |
| Target | PDCD1 | “PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.” NCT03311789 ↗ |